0
0
NEW DELHI — In a major step toward regional healthcare self-reliance, a high-level five-day knowledge exchange workshop between India and Sri Lanka officially commenced today at the Sushma Swaraj Bhawan. The initiative, focused on Health Technology Assessment (HTA), marks a strategic effort to share evidence-based tools that help governments decide which medicines, devices, and medical procedures offer the best value for public money.
The workshop is hosted by the Department of Health Research (DHR) and the Ministry of External Affairs, bringing together senior health officials from both nations to build a framework for affordable healthcare. As both countries strive toward Universal Health Coverage (UHC), the collaboration aims to ensure that life-saving medical innovations are not just available, but economically sustainable for the millions who rely on public health systems.
A New Frontier in Medical Diplomacy
The opening session was led by Dr. Rajiv Bahl, Secretary of the DHR and Director General of the Indian Council of Medical Research (ICMR). Dr. Bahl characterized the workshop as a “significant strategic milestone” in bilateral relations.
“This is more than just a technical meeting; it is an act of healthcare diplomacy,” Dr. Bahl stated during his welcome address. He emphasized that India is committed to supporting its neighbors by sharing the institutional blueprint of HTAIn (Health Technology Assessment India), the body responsible for vetting medical technologies before they are introduced into India’s public schemes.
Smt. Anu Nagar, Additional Secretary at the DHR, echoed this sentiment, noting that the exchange would help Sri Lanka “institutionalize” its own assessment processes. By adopting these rigorous evaluation methods, Sri Lanka can better navigate the complex global market for medical supplies and prioritize treatments that yield the highest health benefits.
What is Health Technology Assessment (HTA)?
For the average citizen, the world of medical procurement often feels like a “black box.” HTA is the systematic process designed to open that box. It evaluates a health intervention—whether it is a new cancer drug, a diagnostic tool like a portable ECG, or a large-scale vaccination program—based on several key pillars:
-
Clinical Effectiveness: Does the technology actually work better than what we already have?
-
Cost-Effectiveness: Is the price justified by the health improvement it provides?
-
Equity: Will this technology reach the marginalized, or only the wealthy?
-
Ethics and Safety: Are there long-term risks or social implications to consider?
“HTA acts as a bridge between the world of research and the world of policy,” says Dr. Roderico H. Ofrin, WHO Representative to India, who has frequently advocated for evidence-informed decision-making. “It ensures that for every rupee or rupee spent, the maximum amount of health is gained for the population.”
The Economic Stake: Reducing Out-of-Pocket Costs
One of the most pressing public health issues in the Global South is high out-of-pocket (OOP) expenditure. According to the World Health Organization (WHO), millions of people fall into poverty every year due to the cost of medicines and hospital stays.
In India, HTAIn has already demonstrated its worth. Recent studies suggest that investments in HTA evaluation can yield returns ranging from 5:1 to 40:1. For example, by evaluating the cost-effectiveness of medical devices like safety-engineered syringes or neonatal resuscitators, HTAIn helps the government negotiate lower prices and ensures that public insurance schemes, such as Ayushman Bharat, cover treatments that truly save lives without breaking the bank.
For Sri Lanka, which has faced significant economic challenges in recent years, this methodology is critical. A robust HTA framework will allow the Sri Lankan Ministry of Health to make “pricing and procurement decisions” with greater transparency, potentially saving the treasury millions while improving patient outcomes.
Navigating Challenges and Counterarguments
While the benefits of HTA are clear, the process is not without its critics or hurdles. Some medical professionals argue that a “cost-first” approach might delay the introduction of cutting-edge, albeit expensive, treatments.
-
Data Scarcity: Reliable HTA requires massive amounts of high-quality data. In many developing nations, the infrastructure to track long-term patient outcomes is still being built.
-
Innovation vs. Access: Pharmaceutical and medical device companies often argue that rigorous HTA “price caps” can stifle innovation. However, proponents argue that HTA actually encourages “value-based innovation”—products that are specifically designed to be affordable and effective in resource-constrained settings.
-
Technical Complexity: As one academic noted in a recent WHO-partnered study, “Policymakers, especially clinicians, sometimes mistrust models. They want to see real-world results, not just mathematical projections.”
Addressing these concerns is a core goal of the five-day workshop. The curriculum includes sessions on governance, methodology, and stakeholder consultation, ensuring that clinicians, patients, and industry leaders all have a seat at the table.
Looking Ahead: A Healthier Neighborhood
The workshop will conclude later this week with a roadmap for future collaborative initiatives. By strengthening the HTA capacities of both India and Sri Lanka, the two nations are setting a precedent for the WHO South-East Asia Region.
As India continues to champion the philosophy of “Vasudhaiva Kutumbakam” (The World is One Family), this exchange serves as a practical application of that ideal—using science and data to ensure that no patient is left behind due to the high cost of technology.
Reference Section
Primary Sources & Citations:
-
Press Information Bureau (PIB) Delhi: “Five-day India–Sri Lanka HTA Workshop begins at Sushma Swaraj Bhawan today,” Release ID: 2225648 (Feb 09, 2026).
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
